(•‿-) Why the whole world is waiting for Viromed Medical $VME - Lots of TAM – TAM

Viromed Medical ($VME) has developed PulmoPlast, a device using cold plasma to treat ventilator-associated pneumonia (VAP), a significant issue in hospitals. The author argues for a large total addressable market (TAM) and a recurring revenue model from sterile consumables. Recent scientific validation from Hannover Medical School supports the technology's efficacy and safety. The author projects a price target of €18.4 (+190%) over the next 3 years, based on a calculated 'fair P/E ratio' of 25.8, considering it a top 25 stock with high potential.